New insights into DHFR interactions: Analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-ω- carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions

Proteins: Structure, Function and Genetics

Volumn 65, Issue 4, 2006, Pages 959-969

  Cody, Vivian ^a   Pace, Jim ^a   Chisum, Kim ^a   Rosowsky, Andre ^b  

^a HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AIDS; Antifolates; Conformational analysis; Dihydrofolate reductase; Mouse; Parallel ring stacking; Pneumocystis carinii

Indexed keywords

2,4 DIAMINO 5 [2 METHOXY 5 (4 CARBOXYBUTYLOXY)BENZYL]PYRIMIDINE; 2,4 DIAMINO 5 [3',4' DIMETHOXY 5' (5 CARBOXY 1 PENTYNYL)]BENZYLPYRIMIDINE; ASPARAGINE; CARBENE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; PHENYLALANINE; PY 1011; PY 957; PY 981; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRIMETHOPRIM DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BETA SHEET; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; ENZYME INHIBITOR INTERACTION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; MOUSE; NONHUMAN; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN STABILITY; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; FOLIC ACID ANTAGONISTS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NADP; PNEUMOCYSTIS CARINII; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM;

PNEUMOCYSTIS CARINII;

EID: 33751092267     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21131     Document Type: Article

References (43)

1. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-2498.
2. Wakefield A. Pneumocystis carinii. Br Med Bull 2002;61:175-188.
3. Stringer JR, Beard CB, Miller RF, Wakefield AE. A New Name (Pneumocystis jirovecii) for Pneumocystis from Humans. Emerg Infect Dis 2002;8:891-896.
4. Rosowsky A, Forsch RA, Queener SF. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-Diamino-5-[2-methoxy-5-(ω-carboxyalky-loxy)benzym]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. J Med Chem 2002;45:233-241.
5. Rosowsky A, Forsch RA, Queener SF. Further studies on 2,4-Diamino-5-(2′,5′-disubstituted benzyl) pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. J Med Chem 1003;46:1726-1736.
6. Forsch RA, Queener SF, Rosowsky A. Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium. Bioorg Med Chem Lett 2004;14:1811-1815.
7. Ma L, Borio L, Masur H, Kovacs JA. Pneumocystis carinii dihydroperoate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999;180:1969-1978.
8. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother 2004;48:4301-4305.
9. Kuyper LF, Roth B, Baccanari DP, Ferone R, Beddell CR, Champness JN, Stammers DK, Dann JG, Norrington FE, Baker DJ, Goodford PJ. Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues. J Med Chem 1985;25:1122,1123.
10. Kuyper LF, Roth B, Baccanari DP, Ferone R, Beddell CR, Champness JN, Stammers DK, Dann JG, Norrington FE, Baker DJ, Goodford PJ. Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues. J Med Chem 1985;28:303-311.
11. 1H NMR study of the interactions and conformations of rationally designed brodimoprim analogues in complexes with Lactobacillius casei dihydrofolate reductase. J Med Chem 1984;27:1672-1676.
12. Morgan WD, Birdsall B, Polshalov VL, Sali D, Kompis I, Feeney L. Solution structure of a brodimoprim analogue in its complex with Lactobacillus casei dihydrofolate reductase. Biochemistry 1995;34:11690-11702.
13. Baker DJ, Beddell CR, Champness JN, Goodford PJ, Norrington FE, Smith DR, Stammers DK. The binding of trimethoprim to bacterial dihydrolate reductase. FEBS Lett 1981;126:49-52.
14. Matthews DA, Bolin JT, Burridge JM, Filman DJ, Volz KW, Kaufman BT, Beddell CR, Champness JN, Stammers DK, Kraut J. Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim. J Biol Chem 1985;260:381-391.
15. Martorell G, Gradwell MJ, Birdsall B, Bauer CJ, Frenkiel TA, Cheung HTA, Polshakov VI, Kuyper L, Feeney J. Solution structure of bound trimethoprim in its complex with Lactobacillus casei dihydrofolate reductase. Biochemistry 1994;33:12416-12426.
16. Polshav VI, Smirnov EG, Birdsall B, Kelly G, Feeney J. Letter to the editor: NMR-based solution structure of the complex of Lactobacillus casei dihydrofolate reductase with trimethoprim and NADPH. J Biomol NMR 2002;24:67-70.
17. Li R, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, Athappilly F, Turley S, Hol WGJ. Three dimensional structure of M. tuberculosis dihydrofolate reductase reveals oppor tunities for the design of novel tuberculosis drugs. J Mol Biol 2000;295:307-323.
18. Matthews DA, Bolin JT, Burridge JM, Filman DJ, Volz KW, Kraut J. Dihydrofolate reductase: the stereochemistry of inhibitor selectivity. J Biol Chem 1985;260:392-399.
19. Groom CR, Thillet J, North ACT, Pictet R, Geddes AJ. Trimethoprim binds in a bacterial mode to the wild-type and E30D mutant of mouse dihydrofolate reductase. J Biol Chem 1991;266:19890-19893.
20. Champness JN, Stammers DK, Beddell CR. Crystallographic investigation of the cooperative interaction between trimethoprim, reduced cofactor and dihydrofolate reductase. FEBS Lett 1986;199:61-67.
21. Champness JN, Achari A, Ballantine SP, Bryant PK, Delves CJ, Stammers DK. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9Å resolution. Structure. 1994;2:915-924.
22. Cody V. Structure analysis of human dihydrofolate reductase complexes with trimethoprim and epiroprim. In Proceedings of the International Union of Crystallography Congress, Geneva, Switzerland; 2002.
23. Kovalevskaya NV, Smurnyy YD, Polshakov VI, Birdsall B, Bradbury AF, Frenkiel T, Feeney J. Solution structure of human dihydrofolate reductase in its complex with trimethoprim and NADPH. J Biomol NMR 2005;33:69-72.
24. Jayalashmi V, Krishna NR. Determination of the conformation of trimethoprim in the binding pocket of bovine dihydrofolate reductase from a STD-NMR intensity-restrained CORECEMAST optimization. J Am Chem Soc 2005;127:14080-14084.
25. Dale GE, Broger C, D'Arcy A, Hartman PG, DeHoogt R, Jolidon S, Kompis I, Labhardt AM, Langen H, Locher H, Page MGP, Stuber D, Then RL, Wipf B, Oefner C. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J Mol Biol 1997;266:23-30.
26. Cody V, Chan D, Galitsky N, Rak D, Luft JR, Pangborn W, Queener SF, Laughton CA, Stevens MFG. Structural studies on bioactive compounds. 30 crystal structure and molecular modeling studies on the Pneumocystis carinii dihydrofolate reductase cofactor complex with TAB, a highly selective antifolate. Biochemistry 2000;39:3556-3564.
27. Yuvaniyama J, Chitnumsub P, Kamchonwongwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, Walkinshaw MD, Yuthavong Y. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003;10:357-365.
28. Kongsaeree P, Khongsuk P, Leartssakulpanich U, Chinumsub P, Tarnchompoo B, Walkinshaw MD, Yuthavong Y. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA 2005;102:13046-13051.
29. Delves CJ, Ballantine SP, Tansik RL, Baccanari DP, Stammers DK. Refolding of recombinant Pneumocystis carinii dihydrofolate reductase and characterization of the enzyme. Protein Expr Purif 1993;4:16-23.
30. Pineda P, Kanter A, McIvor RS, Benkovic SJ, Rosowsky A, Wagner CR. Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate. J Med Chem 2003;46:2816-2818.
31. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-326.
32. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang J-S, Juszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Crystallography and the NMR system: a new software suite macromolecular structure determination. Acta Crystallogr D 1998;54:905-921.
33. Sack JS. CHAIN: a crystallographic modeling program. J Mol Graph 1988;6:224, 225.
34. Evans SV. SETOR. J Mol Graph 1993;11:134-138.
35. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-291.
36. +. Biochemistry 1999;38:4303-4312.
37. Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Queener SF. Structure-based enzyme inhibitor design: modeling studies and crystal structure analysis of Pneumocystis carinii dihydrofolate reductase ternary complex with PT653 and NADPH. Acta Crystallogr D 2002;58:946-954.
38. Cody V, Galitsky N, Luft JR, Pangborn W, Queener SF, Gangjee A. Analysis of quinazoline and pyridopyrimidine reverse bridge N9-C10 bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase. Acta Crystallogr D 2002;58:1393-1399.
39. Cody V, Luft JR, Pangborn W, Gangjee A, Queener SF. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations of enzyme selectivity and stereochemistry. Acta Crystallogr D 2004;60:646-655.
40. Cody V, Luft JR, Pangborn W. Understanding the Role of Leu22 variants in methotrexate resistance: comparison of wild-type and Leu22Arg variant mouse and human dihydrofolate reductase ternary crystal complexes with methotrexate and NADPH. Acta Crystallogr D 2005;61:147-155.
41. Guex N, Diemoud A, Peitsch M, Schoede T. Swiss-Prot DeepView. Available online at http://www.expasy.org/spdbv/
42. Burley SK, Petsko GA. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science 1985;229:23-28.
43. Singh J, Thornton JM. Atlas of protein side chain interactions (2 Vols.). Oxford, UK: Oxford University Press; 1992.